Cargando…

Utilization of Synthetic Human Angiotensin II for Catecholamine-Resistant Vasodilatory Shock in Critically Ill Children: A Single-Center Retrospective Case Series

OBJECTIVES: To describe our institutional experience utilizing adjunctive synthetic angiotensin II in critically ill children with catecholamine-resistant vasodilatory shock (CRVS). DESIGN: Single-center, retrospective case series. SETTING: PICU and cardiac ICU (CICU) at a large, quaternary children...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tezel, Oguzhan, Hutson, Tamara K., Gist, Katja M., Chima, Ranjit S., Goldstein, Stuart L., Stanski, Natalja L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499081/ https://www.ncbi.nlm.nih.gov/pubmed/37711646 http://dx.doi.org/10.1097/CCE.0000000000000978

Ejemplares similares

Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock
por: Bellomo, Rinaldo, et al.
Publicado: (2020)

Synthetic Human Angiotensin II in Pediatric Patients With Vasodilatory Shock: A Report on Two Patients
por: Bailey, Dwight M., et al.
Publicado: (2019)

Renin and Survival in Patients Given Angiotensin II for Catecholamine-Resistant Vasodilatory Shock. A Clinical Trial
por: Bellomo, Rinaldo, et al.
Publicado: (2020)

A Risk Stratified Assessment of Biomarker Based Acute Kidney Injury Phenotypes in Children
por: Stanski, Natalja L., et al.
Publicado: (2023)

Increasing angiotensin-converting enzyme concentrations and absent angiotensin-converting enzyme activity are associated with adverse kidney outcomes in pediatric septic shock
por: Pode-Shakked, Naomi, et al.
Publicado: (2023)

Angiotensin II in vasodilatory shock: lights and shadows
por: Antonucci, Elio, et al.
Publicado: (2017)

Angiotensin II: a new therapeutic option for vasodilatory shock
por: Bussard, Rachel L, et al.
Publicado: (2018)

Angiotensin II for the treatment of vasodilatory shock: enough data to consider angiotensin II safe?
por: Buchtele, Nina, et al.
Publicado: (2018)

Outcomes in Patients with Vasodilatory Shock and Renal Replacement Therapy Treated with Intravenous Angiotensin II
por: Tumlin, James A., et al.
Publicado: (2018)

Angiotensin II infusion in COVID-19-associated vasodilatory shock: a case series
por: Zangrillo, Alberto, et al.
Publicado: (2020)

How Effective is Angiotensin II in Decreasing Mortality of Vasodilatory Shock? A Systematic Review
por: Semedi, Bambang Pujo, et al.
Publicado: (2023)

Vasopressin in vasodilatory shock: is the heart in danger?
por: Hauser, Balázs, et al.
Publicado: (2008)

Vasopressin and terlipressin in adult vasodilatory shock
por: Polito, Angelo, et al.
Publicado: (2012)

Subphenotypes of acute kidney injury in children
por: Gist, Katja M., et al.
Publicado: (2022)

VASOPRESSOR-RESISTANT HYPOTENSION, COMBINATION VASOPRESSOR THERAPY, AND SHOCK PHENOTYPES IN CRITICALLY ILL ADULTS WITH VASODILATORY SHOCK
por: Priyanka, Priyanka, et al.
Publicado: (2022)

Early norepinephrine decreases fluid and ventilatory requirements in pediatric vasodilatory septic shock
por: Ranjit, Suchitra, et al.
Publicado: (2016)

Sensitivity to angiotensin II dose in patients with vasodilatory shock: a prespecified analysis of the ATHOS-3 trial
por: Ham, Kealy R., et al.
Publicado: (2019)

Advances in Vasodilatory Shock: A Concise Review
por: Lahiry, Sandeep, et al.
Publicado: (2019)

Electrolyte derangements in critically ill children receiving balanced versus unbalanced crystalloid fluid resuscitation
por: Stanski, Natalja L., et al.
Publicado: (2022)

Risk factors for severe vasodilatory shock after cardiac surgery
por: Almeida, J, et al.
Publicado: (2015)

Vasopressin in vasodilatory shock: hemodynamic stabilization at the cost of the liver and the kidney?
por: Bracht, Hendrik, et al.
Publicado: (2007)

Physiologic Response to Angiotensin II Treatment for Coronavirus Disease 2019–Induced Vasodilatory Shock: A Retrospective Matched Cohort Study
por: Leisman, Daniel E., et al.
Publicado: (2020)

Initiating angiotensin II at lower vasopressor doses in vasodilatory shock: an exploratory post-hoc analysis of the ATHOS-3 clinical trial
por: Wieruszewski, Patrick M., et al.
Publicado: (2023)

Vasopressin in pediatric vasodilatory shock: a multicentred randomized controlled trial
por: Choong, K, et al.
Publicado: (2009)

Refractory vasodilatory shock secondary to metformin overdose supported with VA ECMO()
por: Ives Tallman, Crystal, et al.
Publicado: (2021)

Optimal target blood pressure in critically ill adult patients with vasodilatory shock: A systematic review and meta-analysis
por: Yoshimoto, Hidero, et al.
Publicado: (2022)

Vasopressin in vasodilatory shock: ensure organ blood flow, but take care of the heart!
por: Dünser, Martin W, et al.
Publicado: (2006)

Vasopressin for the treatment of vasodilatory shock: an ESICM systematic review and a meta-analysis
por: Polito, A, et al.
Publicado: (2011)

Antioxidant Role in Critically Ill Patients with Vasodilatory Shock: Does Glutathione Peroxidase Correlate to Severity of Tissue Hypoxia and Organ Failure
por: Semedi, Bambang Pujo, et al.
Publicado: (2023)

Gene Expression Scoring of Immune Activity Levels for Precision Use of Hydrocortisone in Vasodilatory Shock
por: Yao, Lijing, et al.
Publicado: (2022)

Methylene blue for vasodilatory shock in the intensive care unit: a retrospective, observational study
por: Naoum, Emily E., et al.
Publicado: (2022)

Optimal target blood pressure in critically ill adult patients with vasodilatory shock: a protocol for a systematic review and meta-analysis
por: Fukui, Satoshi, et al.
Publicado: (2021)

Terlipressin in the treatment of catecholamine resistant septic shock
por: Auzinger, GM, et al.
Publicado: (2002)

Vasopressin use in critically ill cirrhosis patients with catecholamine-resistant septic shock: The CVICU cohort
por: Myc, Lukasz A, et al.
Publicado: (2017)

Catecholamine pharmacokinetics and pharmacodynamics in critical illness
por: Johnston, AJ, et al.
Publicado: (2003)

Parathyroid Hormone’s Acute Effect on Vasodilatory Function
por: Farahnak, P., et al.
Publicado: (2010)

Effect of renal denervation on catecholamines and the renin–angiotensin–aldosterone system
por: Feyz, Lida, et al.
Publicado: (2020)

Prognostic and predictive enrichment in sepsis
por: Stanski, Natalja L., et al.
Publicado: (2019)

"Vasopressor Support Sparing Strategies": a Concept to be Incorporated as a Paradigm in the Treatment of Vasodilatory Shock
por: Evora, Paulo Roberto B., et al.
Publicado: (2019)

Efficacy and safety of methylene blue in patients with vasodilatory shock: A systematic review and meta-analysis
por: Zhao, Cong-Cong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0krcsfhifu0b0jn2co101sjm5a